Compare ADPT & STEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | STEL |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2019 | 2017 |
| Metric | ADPT | STEL |
|---|---|---|
| Price | $13.56 | $37.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $17.78 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 1.6M | 229.4K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | ★ $276,976,000.00 | $6,282,000.00 |
| Revenue This Year | $3.98 | $10.14 |
| Revenue Next Year | $22.72 | $4.65 |
| P/E Ratio | ★ N/A | $70.74 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $8.50 | $26.08 |
| 52 Week High | $20.76 | $40.21 |
| Indicator | ADPT | STEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 48.37 |
| Support Level | $12.22 | $36.95 |
| Resistance Level | $15.38 | $38.10 |
| Average True Range (ATR) | 0.79 | 0.61 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 27.88 | 28.57 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc. and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.